Scholar Rock Holding Corporation Common Stock SRRK
Analyst Ratings
- Consensus
- Buy — 14 Buy · 1 Hold · 0 Sell (15 analysts)
- Avg. Price Target
- $66.87 (+34.1% upside)
Key Stats
- Today's Range
- $49.25 – $51.73
- 50-Day Range
- $45.73 – $61.76
- 52-Week Range
- $27.07 – $61.76
- Volume
- 2.49 million shs
- Average Volume
- 1.77 million shs
- Market Cap
- $6.07 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 23.92
- Price / Sales
- —
Short Interest
- Short Interest
- 0.11%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- —
- Net Income
- $-408,591,000
- Net Margin
- —
- Return on Equity
- -161.00%
- Debt-to-Equity
- —
About Scholar Rock Holding Corporation Common Stock
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Related Stocks
Compare head-to-head: SRRK vs AMGN·SRRK vs MRNA·SRRK vs HALO·SRRK vs TWST
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.